BPCP.L
BioPharma Credit PLC
LSEGBpEQUITY
DELAYED
Last price
71.50
▼ 0.10 (0.14%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Tool
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
71.54
Prev close
71.60
Day high
71.56
Day low
71.33
Volume
32.74K
Market cap
—
P/E (TTM)
11.53
52W range
0.64 – 71.56
Day trading desk
Gap from prior close
—
—
VWAP
71.48
+0.02% from price
Relative volume
2.50×
Unusually busy
Session range
0.32%
71.33 – 71.56
Position in range
73%
Near session high
ATR (14D)
—
Daily true range
Prior day high
—
PDH
Prior day low
—
PDL
Bid / ask spread
—
Quote not published
Session volume
36.79K
Avg 14.70K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on BPCP.L open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
74.04M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jul 31, 26 | Hyman (Harry Abraham) |
BUY | 76 | $73 | Direct |
| Jul 31, 26 | Reynolds (Nigel) |
BUY | 27.13K | $26.31K | Direct |
| May 31, 26 | BioPharma Credit PLC |
— | 0 | — | Direct |
| May 29, 26 | Hyman (Harry Abraham) |
BUY | 75 | $72 | Direct |
| May 26, 26 | BioPharma Credit PLC |
BUY | 150.00K | $142.50K | Direct |
| May 22, 26 | BioPharma Credit PLC |
BUY | 800.00K | $760.00K | Direct |
| May 21, 26 | BioPharma Credit PLC |
BUY | 250.00K | $237.50K | Direct |
| May 20, 26 | BioPharma Credit PLC |
BUY | 1.00M | $950.00K | Direct |
| May 15, 26 | BioPharma Credit PLC |
BUY | 50.00K | $47.00K | Direct |
| May 6, 26 | BioPharma Credit PLC |
BUY | 500.00K | $470.00K | Direct |
| Apr 30, 26 | BioPharma Credit PLC |
— | 0 | — | Direct |
| Apr 29, 26 | BioPharma Credit PLC |
BUY | 925.00K | $869.50K | Direct |
| Apr 27, 26 | BioPharma Credit PLC |
BUY | 350.00K | $329.00K | Direct |
| Apr 27, 26 | Adage Capital Partners, L.P. |
— | 56.54M | — | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
Adage Capital Partners, L.P. |
— | 56.17M | Decrease |
BioPharma Credit PLC |
— | 251.74M | Holding |
Hyman (Harry Abraham) |
— | 104.34K | Bought |
Inteligo Bank, Ltd. |
— | 66.59M | Annual Return |
Interseguro Compa��a de Seguros de Vida S.A. |
— | 72.79M | Annual Return |
Newton Investment Management, Ltd. |
— | 136.38M | Annual Return |
Prudential Plc |
— | 67.22M | Annual Return |
Sarasin & Partners, L.L.P. |
— | 70.48M | Annual Return |
Shah (Sapna) |
— | 139.49K | Bought |
Soderstrom (Rolf Kristian Berndtson) |
— | 200.00K | Annual Return |
Fundamentals
Market cap—
Enterprise value$803.84M
Revenue (TTM)$157.75M
Gross profit$157.75M
EBITDA—
Net income$129.89M
EPS (TTM)$0.06
Free cash flow$59.03M
Total cash$12.59M
Total debt$0
Book value / share$0.76
Shares outstanding1.37B
Float1.13B
Short % of float—
Dividend yield—
Beta (5Y)0.18
Valuation & profitability ratios
Trailing P/E11.53
Forward P/E—
PEG ratio—
Price / sales—
Price / book93.69
EV / revenue5.10
EV / EBITDA—
Gross margin100.00%
Operating margin77.19%
Profit margin82.34%
Return on equity11.14%
Return on assets6.85%
Debt / equity—
Current ratio3.77
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $132.06M | $124.46M | $110.49M | $184.25M | — | +6.1% |
| Operating revenue | $132.06M | $124.46M | $110.49M | $184.25M | — | +6.1% |
| Selling, general & admin | $2.30M | $2.15M | $2.04M | $1.90M | — | +7.2% |
| Total operating expense | $2.17M | $2.28M | $2.04M | $1.93M | — | -4.9% |
| Pre-tax income | $129.89M | $122.18M | $108.45M | $182.31M | — | +6.3% |
| Tax provision | $0 | $0 | $0 | $0 | — | — |
| Net income | $129.89M | $122.18M | $108.45M | $182.31M | — | +6.3% |
| Net income to common | $129.89M | $122.18M | $108.45M | $182.31M | — | +6.3% |
| Basic EPS | — | 0.10 | 0.08 | 0.13 | 0.06 | — |
| Diluted EPS | — | 0.10 | 0.08 | 0.13 | 0.06 | — |
| Basic shares | — | 1.22B | 1.31B | 1.36B | 1.37B | — |
| Diluted shares | — | 1.22B | 1.31B | 1.36B | 1.37B | — |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $12.59M | $5.62M | $86.20M | $120.53M | +124.0% |
| Total assets | $1.17B | $1.20B | $1.36B | $1.36B | -2.6% |
| Total liabilities | $17.56M | $17.94M | $15.87M | $26.56M | -2.1% |
| Shareholder equity | $1.15B | $1.18B | $1.34B | $1.34B | -2.6% |
| Net tangible assets | $1.15B | $1.18B | $1.34B | $1.34B | -2.6% |
| Shares issued | 1.37B | 1.37B | 1.37B | 1.37B | 0.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | $129.89M | $122.18M | $108.45M | $182.31M | +6.3% |
| Change in working capital | -$21.24M | -$10.36M | -$9.22M | $7.88M | -105.0% |
| Operating cash flow | $91.09M | $111.91M | $123.18M | $184.28M | -18.6% |
| Investing cash flow | $77.48M | $39.07M | -$1.66M | $48.19M | +98.3% |
| Share buybacks | -$51.27M | -$105.75M | -$17.22M | -$50.09M | +51.5% |
| Dividends paid | -$110.38M | -$174.66M | -$89.77M | -$156.54M | +36.8% |
| Financing cash flow | -$161.65M | -$280.42M | -$106.99M | -$206.62M | +42.4% |
| Free cash flow | $91.09M | $111.91M | $123.18M | $184.28M | -18.6% |
| End cash position | $12.59M | $5.62M | $135.05M | $120.53M | +124.0% |
No filings published for this symbol yet.
Newly listed companies often have nothing on file until their first annual report.
Newly listed companies often have nothing on file until their first annual report.
| Line item | 2025-12-31 | 2024-12-31 | YoY |
|---|---|---|---|
| Cash & equivalents | $12.59M | $5.62M | +124.0% |
| Total assets | $1.17B | $1.20B | -2.6% |
| Total liabilities | $17.56M | $17.94M | -2.1% |
| Shareholder equity | $1.15B | $1.18B | -2.6% |
| Net tangible assets | $1.15B | $1.18B | -2.6% |
| Shares issued | 1.37B | 1.37B | 0.0% |
No filings published for this symbol yet.
Newly listed companies often have nothing on file until their first annual report.
Newly listed companies often have nothing on file until their first annual report.
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | — | — | $0 | — |
| Next quarter | — | — | $0 | — |
| Current year | — | — | $0 | — |
| Next year | — | — | $0 | — |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
ConsensusNONE
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders6.56%
Held by institutions54.93%
Institutions holding81
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
—
—
SMA 20
—
—
SMA 50
—
—
SMA 100
—
—
SMA 200
—
—
EMA 12
—
—
EMA 26
—
—
EMA 50
—
—
RSI (14)
—
—
MACD (12,26,9)
—
Hist —
ATR (14)
—
—
Realised vol 30D
—
Annualised
Bollinger upper
—
20, 2σ
Bollinger lower
—
20, 2σ
50 / 200 cross
—
—
Trend bias
—
—
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
—
—
Correlation to SPY
—
—
Realised vol 30D
—
Annualised
Market vol 1Y
—
SPY, annualised
Max drawdown 1Y
—
Peak to trough
Max drawdown 5Y
—
Peak to trough
ATR 14
—
Average true range
Beta (reported)
0.18
5Y monthly, from filing
Headlines
Novotech Strengthens Presence in Japan with Opening of Tokyo Office
Business Wire · 5m ago
Dow Jones Futures: Tariffs In Focus; Nvidia, Warsh Ahead
Investor's Business Daily · 11m ago
Medtronic vs. Thermo Fisher: Which Healthcare Turnaround Offers More Upside?
Insider Monkey · 13m ago
The Cannabis M&A Wave Is Here. Curaleaf Proved It. Here's Whether Green Thumb Should Ride It -- or Wait to Be Swept Up.
Motley Fool · 16m ago
Prediction: Oklo Won't Book Its First Commercial Power Revenue Before 2028
Motley Fool · 20m ago
Abbott vs. Thermo Fisher: Which is the Better Investment, Diversification or Recovery?
Insider Monkey · 23m ago
Syria says Israel talks addressed de-escalation, staying out of Israel-Turkey tensions
AFP · 29m ago
FIA Hails Success of Landmark INDYCAR Freedom 250 Grand Prix as Motorsport Takes Centre Stage in Washington D.C.
Business Wire · 33m ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.